EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing

Yehui Sun iD, Yu-Chung Pien iD, Yufen Xiao iD, Wei Tan iD, Efrain Sanchez-Ortiz iD, Mateusz Z Durbacz, Zexiang Chen, John R McAnally iD, Yu Zhang iD, Hui Li iD, Andreas C Chai, Francesco Chemello iD und 8 weitere

Proceedings of the National Academy of Sciences · 26.05.2026 · 123 (21)

DOI: 10.1073/pnas.2528477123 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, online erschienen am 18.05.2026. Verfasst von Yehui Sun und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern …. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Nanoparticles, Lipids, Gene Editing. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NCI NIH HHS, NHLBI NIH HHS, HHS | NIH | National Cancer Institute (NCI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

RNA therapeutics offer promising potential for treating heart disease; however, their clinical application has been limited by insufficient cardiac delivery. Here, we developed a screening platform using human induced pluripotent stem cell–derived cardiomyocytes (hiPSC-CMs) to identify human cardiotropic lipid nanoparticles (LNPs). By screening a chemically diverse LNP library, we identified a lead LNP, 18:1 TAP10, with potent human cardiac transfection capability. Using the Ai14 LoxP-Stop-LoxP-tdTomato reporter mouse model, we assessed 18:1 TAP10 LNP delivery of Cre mRNA in vivo via four administration routes (intravenous, intrathoracic, intracoronary, and intramyocardial (IM)) and found that each administration path enabled both the spatial distribution and cellular tropism in the heart to varying degrees. While all routes achieved robust transfection across non-CM populations (up to 40% in endothelial cells), IM injection notably enabled substantial CM transfection (36% at injection site, 13% distally). To demonstrate therapeutic potential, 18:1 TAP10 LNPs were used to deliver adenine base editor (ABE) components to Duchenne muscular dystrophy (DMD) patient-derived hiPSC-CMs, resulting in 80% on-target gene correction and restoration of dystrophin expression. In a humanized DMD mouse model, we observed dystrophin-positive cardiomyocytes in the injected left ventricle following IM administration of LNP-ABE. This work establishes a human cell-based platform for discovering organ-tropic delivery vehicles and highlights LNPs as a potential modality for therapeutic mRNA delivery and gene editing in the heart.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myocytes, CardiacNanoparticlesLipidsGene EditingHumansAnimalsMiceInduced Pluripotent Stem CellsMuscular Dystrophy, DuchenneRNA, MessengerLiposomes

Stichwörter der Autor:innen

cardiac deliverygene editinghiPSC-CMslipid nanoparticlemRNA

Substanzen

LipidsLipid NanoparticlesRNA, MessengerLiposomes

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Simmons Comprehensive Cancer Center, Program in Genetic Drug Engineering, The University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Biochemistry, The University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Molecular Biology, The University of Texas Southwestern Medical Center, Dallas, TX 75390.
  • Department of Neurology, The University of Texas Southwestern Medical Center, Dallas, TX 75390.

ORCID-Profile: Yehui Sun, Yu-Chung Pien, Yufen Xiao, Wei Tan, Efrain Sanchez-Ortiz, John R McAnally, Yu Zhang, Hui Li, Francesco Chemello, Fangyu Zhang, Sang M Lee, Priyanka Patel, Denise M Ramirez, Eric N Olson, Daniel J Siegwart

Förderung

  • NCI NIH HHS
  • NHLBI NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • HHS | NIH | National Heart, Lung, and Blood Institute (NHLBI)
  • HHS | NIH | National Institute of Biomedical Imaging and Bioengineering (NIBIB)
  • Welch Foundation (The Welch Foundation)
  • NICHD NIH HHS
  • HHS | NIH | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)

Zitieren

APA

Sun, Y., Pien, Y. C., Xiao, Y., Tan, W., Sanchez-Ortiz, E., Durbacz, M. Z., Chen, Z., McAnally, J. R., Zhang, Y., Li, H., Chai, A. C., Chemello, F., Zhang, F., Lee, S. M., Patel, P., Ramirez, D. M., Chatterjee, S., Liu, N., Olson, E. N., & Siegwart, D. J. (2026). A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing. Proceedings of the National Academy of Sciences, 123(21). https://doi.org/10.1073/pnas.2528477123

Vancouver

Sun Y, Pien YC, Xiao Y, Tan W, Sanchez-Ortiz E, Durbacz MZ, et al. A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing. Proceedings of the National Academy of Sciences. 2026;123(21). doi:10.1073/pnas.2528477123

BibTeX
@article{Sun2026,
  author = {Sun, Yehui and Pien, Yu-Chung and Xiao, Yufen and Tan, Wei and Sanchez-Ortiz, Efrain and Durbacz, Mateusz Z and Chen, Zexiang and McAnally, John R and Zhang, Yu and Li, Hui and Chai, Andreas C and Chemello, Francesco and Zhang, Fangyu and Lee, Sang M and Patel, Priyanka and Ramirez, Denise M and Chatterjee, Sumanta and Liu, Ning and Olson, Eric N and Siegwart, Daniel J},
  title = {A human cardiomyocyte screen identifies optimized lipid nanoparticles for in vivo cardiac gene editing},
  journal = {Proceedings of the National Academy of Sciences},
  year = {2026},
  volume = {123},
  number = {21},
  doi = {10.1073/pnas.2528477123}
}
Kostenlos starten →